Difference between revisions of "Team:Pasteur Paris/Entrepreneurship"

(Prototype team page)
 
 
(26 intermediate revisions by 7 users not shown)
Line 1: Line 1:
−
{{Pasteur_Paris}}
+
{{Pasteur_Paris/MenuBlock}}
 
<html>
 
<html>
  
 +
<style type="text/css">
 +
#runningchip {
 +
left: 125px;
 +
}
 +
#project_small {
 +
background-color: #292929;
 +
}
 +
#bannerchanged{
 +
    width: 100%;
 +
    overflow: hidden;
 +
    margin: 0 auto;
 +
}
 +
@media screen and (max-width: 760px) {
 +
/*#wrapper {
 +
    width: 100%;
 +
    overflow: hidden;
 +
}
 +
#container {
 +
  width: 100%;
 +
    margin: 0 auto;
 +
}*/
 +
.banner-img {
 +
    width: 100%;
 +
}
 +
}
  
 +
</style>
  
−
<div class="column full_size judges-will-not-evaluate">
+
<div id="bannerchanged">
−
<h3>★  ALERT! </h3>
+
                <img class="banner-img" src="https://static.igem.org/mediawiki/2018/4/48/T--Pasteur_Paris--Banner_Entrepreneurship.jpg">
−
<p>This page is used by the judges to evaluate your team for the <a href="https://2018.igem.org/Judging/Medals">medal criterion</a> or <a href="https://2018.igem.org/Judging/Awards"> award listed below</a>. </p>
+
        </div>
−
<p> Delete this box in order to be evaluated for this medal criterion and/or award. See more information at <a href="https://2018.igem.org/Judging/Pages_for_Awards"> Instructions for Pages for awards</a>.</p>
+
<h1></h1>
−
</div>
+
</div>
−
 
+
−
 
+
−
<div class="clear"></div>
+
−
 
+
−
 
+
−
 
+
−
<div class="column full_size">
+
−
 
+
−
<h1>Entrepreneurship</h1>
+
−
 
+
−
</div>
+
−
 
+
−
<div class="column two_thirds_size">
+
−
<h3>Best Supporting Entrepreneurship Special Prize</h3>
+
−
<p>
+
−
In previous years, iGEM had an entrepreneurship track. Teams were encouraged to build projects and focus on commercializing their work. We have now moved to an award as the best work in this area may come from teams who are not solely focused on entrepreneurship.
+
−
</p>
+
−
 
+
−
<p>The Best Supporting Entrepreneurship award recognizes exceptional effort to build a business case and commercialize an iGEM project. This award is open to all teams to show that entrepreneurship is something all teams can aspire to do with their project. This award can go to an new project, or to a previous project that a team aimed to commercialize. Have you filed a provisional patent on your project/device/process? Have you raised money to build and ship products? Have you pitched your idea to investors and received money? As always in iGEM, the aim is to impress the judges!
+
−
 
+
−
<br><br>
+
−
To compete for the <a href="https://2018.igem.org/Judging/Awards">Best Supporting Entrepreneurship prize</a>, please describe your work on this page and also fill out the description on the <a href="https://2018.igem.org/Judging/Judging_Form">judging form</a>.
+
−
<br><br>
+
−
You must also delete the message box on the top of this page to be eligible for this prize.
+
−
</p>
+
−
</p>
+
−
</div>
+
−
 
+
−
<div class="column third_size">
+
−
<div class="highlight decoration_A_full">
+
−
<h3>Inspiration</h3>
+
−
<p>You can look at what other teams did to get some inspiration! <br />
+
−
Here are a few examples:</p>
+
−
<ul>
+
−
<li><a href="https://2016.igem.org/Team:Sydney_Australia">2016 Sydney Australia</a></li>
+
−
<li><a href="https://2016.igem.org/Team:Pasteur_Paris">2016 Pasteur Paris</a></li>
+
−
<li><a href="https://2014.igem.org/Team:UCC_Ireland">2014 UCC Ireland</a></li>
+
−
<li><a href="https://2014.igem.org/Team:Imperial">2014 Imperial College London</a></li>
+
−
</ul>
+
−
</div>
+
−
</div>
+
−
 
+
−
 
+
−
 
+
−
<div class="clear"></div>
+
−
 
+
−
<div class="column full_size">
+
−
<h3>Patents and intellectual property</h3>
+
−
 
+
−
<p>
+
−
If your team is seriously considering commercializing and looking into building a company after the competition, you may want to look at how you are going to protect your work and secure investment. Investors will usually require some form of intellectual protection, so you may want to investigate how to apply for a patent or provisional patent in your country and region before disclosing your project at iGEM. Remember that you can only be evaluated in iGEM based on what you share on your wiki and at the Jamboree, so any work you don't present can't count towards your project. </p>
+
−
 
+
−
<p>This is an area where we are different as we care about sharing, openness and contributing to the community and investors don't always agree with these values. It is up to you and your team to decide what to do. Remember that most universities have a commercialization department and that you can talk to them before coming to a decision.
+
−
</p>
+
−
</div>
+
−
 
+
−
<div class="clear"></div>
+
  
  
 +
<div id="GeneralContent">
 +
<div id="MainContent">
 +
<div class="block full"><h3><a href="https://static.igem.org/mediawiki/2018/2/26/T--Pasteur_Paris--BP.pdf" style="font-weight: bold ; color:#85196a;" target="__blank">Download here our full business plan</a></h3></div>
 +
<div class="block full"><p><i>Since we feel NeuronArch is a promising project in the field of biotechnology and prosthetics, we envisioned it as a startup company and designed a business plan accordingly to the experience we had this year participating at iGEM.</i></p></div>
 +
<div class="block half">
 +
<p>Even though leg prosthetics are becoming more and more efficient and sophisticated, allowing amputees to even participate to Olympic races, arm prosthetics have not evolved that much from the last century, usually equipped on the torso with a harness and are not so practical. While biomechanical prosthetics are slowly entering the market, bionic prosthetics are still missing because current technology does not allow a direct connection between the amputated limb’s nerves and the prosthetics itself. Osseointegrated prosthetics may be the field allowing this connection but the risk of infection by pathogenic biofilms on this type of interface is very high, requiring a heavy antibiotic treatment and removal of the osseointregrated prosthetic. To answer this problem, we used synthetic biology to create an engineered biofilm able to stimulate nerve regrowth after amputation but also reducing the risk of the formation of a pathogenic biofilm. </p>
 +
</div>
 +
<div class="block half">
 +
<img src="https://static.igem.org/mediawiki/2018/1/1d/T--Pasteur_Paris--BP_Figure1.png">
 +
<div class="legend"><b>Figure 1: </b> Year 2005, limb loss estimates by age (United States) <sup>[1]</sup> <b>(A)</b> Data on limb loss for people under and over 65. <b>(B)</b> Distribution of limb loss for people between 18 and 64. <b>(C)</b> Distribution of limb loss between 65 and 100. There is a discrepancy between sums and totals due to rounding.  Values representing less than 1000 is indicated with a*. </div>
 +
</div>
 +
<div class="block full">
 +
<p>Before bringing NeuronArch to an industrial level, we first evaluated our target market, depending on the number of amputation and realized that our device, which would mainly be used by young/active people, was aiming at only a minority of the amputations. In fact, 57% of amputees <sup> [1] </sup> are under 65 years old, and in this group, 66.5% are between the age of 45 and 64 years old, while only 30% are between the age of 18 and 44 years old (Cf. Figure 1). </p>
 +
</div>
 +
<div class="block one-third">
 +
<p> The osseointegrated implant market on one hand, according to Prescient Strategic Intelligence is expected to grow at a compound annual growth rate, which is the measure of growth over multiple time periods, of 4% between 2013 and 2023 <sup> [1] </sup>. The market for orthopedic prosthetics however, is expected to moderately grow in term of value due to increased incidence of trauma and accidental injuries (Cf. Table 1). </p>
 +
</div>
 +
<div class="block two-third center">
 +
<table class="tableData" style="margin: auto;">
 +
<tr>
 +
<td></td>
 +
<td>2005</td>
 +
<td>2010</td>
 +
<td>2020</td>
 +
<td>2050</td>
 +
</tr><tr>
 +
<td>Dysvascular Disease Total</td>
 +
<td>846</td>
 +
<td>969</td>
 +
<td>1285</td>
 +
<td>2272</td>
 +
</tr><tr>
 +
<td>Dysvascular Disease with Comorbidity of Diabetes</td>
 +
<td>592</td>
 +
<td>674</td>
 +
<td>899</td>
 +
<td>1667</td>
 +
</tr><tr>
 +
<td>Trauma</td>
 +
<td>704</td>
 +
<td>769</td>
 +
<td>906</td>
 +
<td>1326</td>
 +
</tr><tr>
 +
<td>Cancer</td>
 +
<td>18</td>
 +
<td>19</td>
 +
<td>22</td>
 +
<td>29</td>
 +
</tr>
 +
<tr>
 +
<td>Total</td>
 +
<td>1568</td>
 +
<td>1757</td>
 +
<td>2213</td>
 +
<td>3627</td>
 +
                                                </tr>
 +
</table>
 +
<div class="legend"><b>Table 1: </b>Expected occurrence of limb loss causes, from 2005 to 2050 in the United States <sup>[2]</sup>.</div>
 +
</div>
 +
<div class="block full">
 +
<p>Introduction of custom-made implant products (rising demands for advanced orthopedic prosthetics, favorable reimbursement for orthopedic prosthetics, rise in prevalence of lifestyle related diseases and disorders, growing focus on containment of healthcare costs and distribution & collaboration agreements to increase product reach driving global revenues) is creating high potential growth opportunities for players operating in global orthopedic prosthetics market. Spur in the disposable household income in the emerging economies are expected to provide ample opportunities to the manufacturers operating in the osseointegrated implants market.</p>
 +
<p>We feel our interface NeuronArch could respond to this demand, and tried our best to tackle every issue that comes with trying to bring NeuronArch to the industrial scale.</p>
 +
<p>In the Business Plan, that you can <a href="https://static.igem.org/mediawiki/2018/2/26/T--Pasteur_Paris--BP.pdf" style="font-weight: bold ; color:#85196a;" target="_blank">download here</a>, you will find a Market Analysis, Study of possible competition by private companies, our Marketing Plan, our Sales Plan, our Operations, details on our Company, as well as our Financial Plan. </p>
 +
</div>
 +
<div class="block separator-mark"></div>
 +
<div class="block title"><h1>REFERENCES</h1></div>
 +
<div class="block full">
 +
<ul style="text-align: left;list-style: disc;">
 +
<li style="list-style-type: decimal">Kathryn Ziegler-Graham, Ellen J. MacKenzie, Patti L. Ephraim, Thomas G. Travison, Ron Brookmeyer. Estimating the Prevalence of Limb Loss in the United States: 2005 to 2050, Archives of Physical Medicine and Rehabilitation (2008). Volume 89, Issue 3, Pages 422-429.<br><br></li>
 +
<li style="list-style-type: decimal">Prescient Strategic Intelligence, “Osseintegration Implants Market” (2018) Retrieved Sep. 10th 2018 from <a href="https://www.psmarketresearch.com/market-analysis/osseointegration-implants-market">https://www.psmarketresearch.com/market-analysis/osseointegration-implants-market</a></li>
 +
</ul>
 +
</div>
 +
 +
</div>
 +
</div>
 
</html>
 
</html>

Latest revision as of 14:50, 10 November 2018

""

Download here our full business plan

Since we feel NeuronArch is a promising project in the field of biotechnology and prosthetics, we envisioned it as a startup company and designed a business plan accordingly to the experience we had this year participating at iGEM.

Even though leg prosthetics are becoming more and more efficient and sophisticated, allowing amputees to even participate to Olympic races, arm prosthetics have not evolved that much from the last century, usually equipped on the torso with a harness and are not so practical. While biomechanical prosthetics are slowly entering the market, bionic prosthetics are still missing because current technology does not allow a direct connection between the amputated limb’s nerves and the prosthetics itself. Osseointegrated prosthetics may be the field allowing this connection but the risk of infection by pathogenic biofilms on this type of interface is very high, requiring a heavy antibiotic treatment and removal of the osseointregrated prosthetic. To answer this problem, we used synthetic biology to create an engineered biofilm able to stimulate nerve regrowth after amputation but also reducing the risk of the formation of a pathogenic biofilm.

Figure 1: Year 2005, limb loss estimates by age (United States) [1] (A) Data on limb loss for people under and over 65. (B) Distribution of limb loss for people between 18 and 64. (C) Distribution of limb loss between 65 and 100. There is a discrepancy between sums and totals due to rounding. Values representing less than 1000 is indicated with a*.

Before bringing NeuronArch to an industrial level, we first evaluated our target market, depending on the number of amputation and realized that our device, which would mainly be used by young/active people, was aiming at only a minority of the amputations. In fact, 57% of amputees [1] are under 65 years old, and in this group, 66.5% are between the age of 45 and 64 years old, while only 30% are between the age of 18 and 44 years old (Cf. Figure 1).

The osseointegrated implant market on one hand, according to Prescient Strategic Intelligence is expected to grow at a compound annual growth rate, which is the measure of growth over multiple time periods, of 4% between 2013 and 2023 [1] . The market for orthopedic prosthetics however, is expected to moderately grow in term of value due to increased incidence of trauma and accidental injuries (Cf. Table 1).

2005 2010 2020 2050
Dysvascular Disease Total 846 969 1285 2272
Dysvascular Disease with Comorbidity of Diabetes 592 674 899 1667
Trauma 704 769 906 1326
Cancer 18 19 22 29
Total 1568 1757 2213 3627
Table 1: Expected occurrence of limb loss causes, from 2005 to 2050 in the United States [2].

Introduction of custom-made implant products (rising demands for advanced orthopedic prosthetics, favorable reimbursement for orthopedic prosthetics, rise in prevalence of lifestyle related diseases and disorders, growing focus on containment of healthcare costs and distribution & collaboration agreements to increase product reach driving global revenues) is creating high potential growth opportunities for players operating in global orthopedic prosthetics market. Spur in the disposable household income in the emerging economies are expected to provide ample opportunities to the manufacturers operating in the osseointegrated implants market.

We feel our interface NeuronArch could respond to this demand, and tried our best to tackle every issue that comes with trying to bring NeuronArch to the industrial scale.

In the Business Plan, that you can download here, you will find a Market Analysis, Study of possible competition by private companies, our Marketing Plan, our Sales Plan, our Operations, details on our Company, as well as our Financial Plan.

REFERENCES

  • Kathryn Ziegler-Graham, Ellen J. MacKenzie, Patti L. Ephraim, Thomas G. Travison, Ron Brookmeyer. Estimating the Prevalence of Limb Loss in the United States: 2005 to 2050, Archives of Physical Medicine and Rehabilitation (2008). Volume 89, Issue 3, Pages 422-429.

  • Prescient Strategic Intelligence, “Osseintegration Implants Market” (2018) Retrieved Sep. 10th 2018 from https://www.psmarketresearch.com/market-analysis/osseointegration-implants-market